Robert Stratta to Immunoglobulin G
This is a "connection" page, showing publications Robert Stratta has written about Immunoglobulin G.
Connection Strength
2.313
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplant Proc. 2005 Oct; 37(8):3527-30.
Score: 0.248
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years. Transplant Proc. 2005 Oct; 37(8):3531-4.
Score: 0.248
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab. Transplant Proc. 2004 May; 36(4):1080-1.
Score: 0.224
-
Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Clin Transplant. 2004; 18 Suppl 12:61-6.
Score: 0.219
-
Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation. 2003 Apr 27; 75(8):1260-6.
Score: 0.209
-
Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis. Transplant Proc. 2002 Aug; 34(5):1903-5.
Score: 0.199
-
Stratta RJ, Alloway RR, Hodge E, Lo A. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant. 2002 Feb; 16(1):60-8.
Score: 0.192
-
Bruce DS, Sollinger HW, Humar A, Sutherland DE, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation. 2001 Nov 27; 72(10):1637-43.
Score: 0.190
-
Stratta RJ, Alloway RR, Lo A, Hodge E. A multicenter trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis. Transplant Proc. 2001 Feb-Mar; 33(1-2):1692-3.
Score: 0.179
-
Rogers J, Stratta RJ, Lo A, Alloway RR. Impact of the metabolic syndrome on long-term outcomes in simultaneous kidney-pancreas transplantation. Transplant Proc. 2005 Oct; 37(8):3549-51.
Score: 0.062
-
Rogers J, Stratta RJ, Lo A, Alloway RR. Inferior late functional and metabolic outcomes in African American simultaneous kidney-pancreas recipients. Transplant Proc. 2005 Oct; 37(8):3552-4.
Score: 0.062
-
Lo A, Stratta RJ, Alloway RR, Hodge EE. A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation. Transplant Proc. 2005 Mar; 37(2):1289-90.
Score: 0.059
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. Does surgical technique influence outcomes after simultaneous kidney-pancreas transplantation? Transplant Proc. 2004 May; 36(4):1076-7.
Score: 0.056
-
Stratta RJ, Rohr MS, Adams PL, Sundberg AK, Hartmann EL, Armstrong G, Anderson TK, Farney AC, Roskopf JA, Hairston G, Kiger DF, Nagaraj SK, Iskandar SS, Assimos DG. Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. Clin Transpl. 2003; 229-45.
Score: 0.051
-
Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation. Transpl Int. 2001 Dec; 14(6):396-404.
Score: 0.047
-
Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber AO. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. Transplant Proc. 2001 Feb-Mar; 33(1-2):1701-3.
Score: 0.045
-
Stratta RJ, Shaefer MS, Cushing KA, Markin RS, Wood RP, Langnas AN, Reed EC, Woods GL, Donovan JP, Pillen TJ, et al. Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation. 1991 Jan; 51(1):90-7.
Score: 0.022